Genentech partners PD-L1 star 'atezo' with Immune Design activator
Just two days after striking a partnership with Merck, Immune Design has come back with another marquee pact. The West Coast biotech has inked a deal to partner its immune system activator CMB305 with Genentech's anti-PD-L1 star atezolizumab (MPDL3280A) in a Phase II study for soft tissue sarcoma.
Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.
Sanofi taps Immune Design to help battle food allergies
Sanofi has reached out to Seattle biotech Immune Design, looking to borrow the company's drug discovery platform to develop new treatments for food allergies.
Biotech IPOs sputter amid downsizings, disappointments and white flags
Six biotechs were expected to go public this week, eyeing nearly $400 million combined, but that potential has so far amounted to one deeply discounted offering, one bottom-of-the-range debut and one outright cancelation.
Three more biotechs target $175M in IPO cash amid market tumult
A new crop of biotech IPO hopefuls has filed to reap a combined $175 million, looking to bankroll efforts in oncology, pain and rare diseases with offerings on an up-and-down market.
Biotechs queue up for $269M in fresh IPOs amid a sector rebound
Four more drug developers are angling to make Wall Street debuts, lining up to raise a combined $269 million as the market for biotech IPOs has shown renewed signs of life after a tepid spring.
Immune Design recruits new team, lands $32.5M for cancer immunotherapies
Over the last few months, Carlos Paya has been filling out his management team at Seattle-based Immune Design. And today the biotech CEO detailed an injection of $32.5 million in venture cash--with the near-term prospect of adding $16.5 million more--to finance the biotech's efforts to nail proof-of-concept data on its two top cancer vaccines.
Former Elan president Carlos Paya has signed on as Immune Design's new CEO. The Seattle-based vaccine developer, which was founded in 2008, is developing therapeutic vaccines for the treatment of
Immune Design lands $212M adjuvant pact with MedImmune
Seattle vaccine upstart Immune Design scored a $212 million licensing deal and some important industry cred with its new pact giving MedImmune the right to use its adjuvant in new vaccines. The deal
Steve Reed uses familiar strategy to build a new biotech
In a follow-up to yesterday's news that Immune Design had raised a $32 million round to fuel its work on a new generation of vaccines, CEO Steve Reed talked to Xconomy's Luke Timmerman about his